01 September 2022 | News
The site's clinical manufacturing operations have an initial capacity of 4,000L and will grow to 6,000L utilizing only single-use technology
Image credit: shutterstock
China's WuXi Biologics, a global leading Contract Research, Development and Manufacturing Organization (CRDMO), has announced the release of its GMP phase I drug substance clinical manufacturing facility, MFG18, in Cranbury, New Jersey, US.
The site's clinical manufacturing operations have an initial capacity of 4,000L and will grow to 6,000L, utilizing only single-use technology, adding to the Cranbury site's full process development capability. It is WuXi Bio's first GMP manufacturing facility in North America and was established in response to the growing need of customers worldwide.
The 154,448 square foot New Jersey location puts WuXi Biologics closer to the majority of its customers headquartered in the U.S. and is situated within a growing biopharma cluster. The facility is a key piece of WuXi Biologics' Global Dual Sourcing Strategy, ensuring that products can be manufactured, and materials sourced at multiple WuXi Biologics locations around the world. The site currently employs over 150 people and anticipates over 250 employees when in full operation.